Apidra 100 Iu/ml 3 ml Cartridge

Apidra 100 lu/ ml 3 ml cartridge is a a rapid acting insulin, used to control blood sugar in patient with type 1 and type 2 diabetes mellitus. The medication active ingredient is Insulin Glulisine (100IU). It acts by facilitating cellular glucose uptake, primarily in muscle and adiptose tissues and inhibiting hepatic glucose production, thereby lowering blood glucose level. This prescription based medication should be used under the guidance of a healthcare professional and follow strict timings to ensure safety of the treatment.

Maintaining blood sugar level

● Hypoglycemia (low blood glucose level)
● Injection site reactions (pain, swelling and redness)
● Rash
● Itching
● Upper respiratory tract infections
● Liposydtrophy (skin thickening)
● Feeling Hungary
● Visual disturbances
● Sweating

Apidra 100IU should be taken 15 minutes before a meal or within 20 minutes after starting the meal. Do not stop taking without the consultation of a doctor. The dosage must be individualized based on the patient's blood sugar levels, meal composition and insulin requirements. Include the medicine with healthy diet, regular exercise, and weight reduction by taking advice to the doctor.

Apidra cartridge is a form of insulin that control blood sugar (glucose). The medicine helps the glucose get into the cells, so the body can use it for energy. This is a form of hormonal therapy which lowers blood sugar within 10- 20 minutes of injecting it and effects can last for 4-5 hours. By lowering sugar level helps reduce the risk of getting any of the serious complications of diabetes such as kidney damage, eye damage and nerve problems.

• Mazzarino, M., Pernice, S., de la Torre, X., & Botrè, F. (2011). A screening procedure for synthetic insulins by an HPLC-chip interfaced to a quadrupole time-of-flight mass spectrometer. In Recent advances in doping analysis (19) (pp. 148-151). Cologne: Sportverlag Straub.
• Thevis, M., Thomas, A., Delahaut, P., Bosseloir, A., & Schänzer, W. (2006). Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography− tandem mass spectrometry. Analytical chemistry, 78(6), 1897-1903.
• Suárez-Casillas, P., Lora-Escobar, S. J., Montecatine-Alonso, E., Li, T., & Acosta-García, H. (2025). Stability of thermolabile drugs at room temperature. A review. Farmacia Hospitalaria.
• Delhi, N., Delhi, N. W., Delhi, W., Delhi, S. W., Delhi, S., & Delhi, S. E. ONLINE SUPPLEMENTARY APPENDIX.
• Dal, O. H., & Sezer, A. D. (2017). Analytical and Sales Data Comparison of Reference Product of Insulin Aspart and its Biosimilar in Turkey. Marmara Pharmaceutical Journal, 21(3), 675-687.
• Attjioui, H., Cheikh, A., Tebaa, A., Zerhouni, M. W., Aliat, Z., Mefetah, H., & Bouatia, M. (2020). The rise of electronic commerce in healthcare: the need to ensure consumer safety. Int J Pharm Sci Res, 11.